• Keap1-Nrf2 Inhibition Suppresses Ferroptosis in Aβ42-Induced

  2026-08-06

  This study introduces compound 4–95, a selective Keap1-Nrf2 protein–protein interaction inhibitor, as a novel agent that ameliorates cognitive deficits in Alzheimer's models by suppressing neuronal ferroptosis. The work reveals that targeting the Keap1–Nrf2–GPX4 axis mitigates amyloid and tau pathology, offering a disease-modifying approach beyond current symptomatic therapies.

• Refined In Vitro Metrics for Cancer Drug Response Evaluation

  2026-08-05

  Schwartz's dissertation introduces a rigorous analytical distinction between proliferative arrest and cell death when evaluating antineoplastic chemotherapy drugs in vitro. This methodological innovation enhances the mechanistic interpretation of drug efficacy, which is particularly relevant for agents like dacarbazine and informs more predictive preclinical cancer research.

• Topotecan vs Cisplatin/Etoposide in First-Line SCLC Therapy

  2026-08-05

  This article dissects the reference study's evaluation of topotecan-based regimens versus the established cisplatin/etoposide protocol in first-line treatment of small cell lung cancer (SCLC). The findings reveal both the efficacy and tolerability profiles of these regimens, highlighting the persistent challenge of relapse and chemotherapy resistance in SCLC clinical management.

• SP600125: Strategic JNK Inhibition for Translational Impact

  2026-08-04

  This article provides translational researchers with an advanced, mechanistic perspective on the selective JNK inhibitor SP600125, blending evidence-based insights with strategic guidance. It contextualizes SP600125’s ATP-competitive inhibition of JNK, discusses its application in apoptosis, inflammation, and cancer research, and offers a forward-looking assessment of its place within the evolving landscape of kinase-targeted translational studies. Key mechanistic findings from recent chemoproteomic advances are linked to practical protocol choices, with actionable recommendations for deploying SP600125 as a precision tool.

• Ceftolozane sulfate (SKU C8753): Reliable Antibacterial Rese

  2026-08-04

  This article explores real-world laboratory challenges in antibacterial research and demonstrates how Ceftolozane sulfate (SKU C8753) from APExBIO supports reproducibility and data quality in cell viability and PK/PD assays. Scenario-driven Q&A blocks offer practical guidance on protocol design, resistance modeling, and vendor selection—anchored in evidence-based recommendations.

• HRP Goat Anti-Mouse IgG (H+L) Antibody: Workflow Parameters

  2026-08-03

  The HRP Goat Anti-Mouse IgG (H+L) Antibody (SKU K1221) enables sensitive, specific detection of mouse IgG in immunoassays such as Western blot, ELISA, and IHC by leveraging an HRP-conjugated, affinity-purified polyclonal design. It is not intended for non-mouse primary antibodies or applications requiring isotype-specific discrimination.

• Cell Tumbling Drives Stem Cell Fate via Nuclear Mechanotrans

  2026-08-03

  Ayushman et al. introduce 'cell tumbling' as a rapid, whole-cell movement in 3D hydrogels that directly enhances stem cell differentiation through nuclear mechanotransduction. Their findings highlight a new physical regulator of cell fate, expanding the landscape of mechanobiology and offering actionable insights for tissue engineering and cancer research.

• Sabutoclax in Precision Oncology: Beyond Conventional Bcl-2

  2026-08-02

  Explore how Sabutoclax, a potent pan-Bcl-2 inhibitor, is redefining apoptosis induction in cancer cells. This article uniquely focuses on assay interpretation, translational model selection, and the practical impact of advanced in vitro response metrics.

• PD98059: MEK Inhibitor for Apoptosis and Neuroprotection Ass

  2026-08-01

  PD98059 stands out as a selective and reversible MEK inhibitor, enabling precise dissection of the MAPK/ERK pathway in cancer and neuroprotection research. This article details hands-on protocols, troubleshooting insights, and the latest evidence on optimizing apoptosis induction and cell cycle arrest models using APExBIO’s PD98059.

• Cisapride (R 51619) in Advanced Cardiac Electrophysiology Re

  2026-07-31

  Cisapride (R 51619) enables predictive cardiac toxicity and electrophysiology research with unparalleled reproducibility in iPSC-derived cardiomyocyte models. Integrating deep learning phenotyping, this compound is a benchmark probe for hERG channel inhibition and 5-HT4 receptor signaling workflows, driving high-content screening and translational safety assessment beyond traditional methodologies.

• Vemurafenib (PLX4032): Advanced Pathway Dynamics in Melanoma

  2026-07-31

  Explore how Vemurafenib (PLX4032) enables advanced, systems-level dissection of melanoma resistance networks. This article provides a unique integration of multi-omics insights and practical assay considerations for BRAF-mutant melanoma research.

• Parathyroid hormone (1-34) (human): Precision Tools for High

  2026-07-30

  Explore the advanced applications of Parathyroid hormone (1-34) (human) in bone metabolism and kidney disease modeling. This article reveals new insights into PTH (1-34) peptide fragment use for robust, translational research, highlighting unique assay design and practical implications.

• Tolazoline in Integrated β-Cell and Airway Models: Decision

  2026-07-30

  Explore Tolazoline as an α2-adrenergic receptor antagonist with dual action in islet and airway models. This article uniquely guides assay selection and experimental design, offering protocol insights and critical paper-based analysis for advanced pharmacological research.

• Silymarin in Advanced Bench Research: Optimizing Milk Thistl

  2026-07-29

  Silymarin, the polyphenolic milk thistle extract, empowers researchers to dissect oxidative stress, cancer, and antiviral pathways with precision. This guide delivers actionable workflows, troubleshooting strategies, and cross-domain insights that maximize Silymarin's impact as a reference compound in experimental systems.

• Propranolol in Translational Neurocardiology: Mechanisms and

  2026-07-29

  Explore how Propranolol, a non-selective β-adrenergic receptor blocker, bridges cardiovascular regulation and emotional memory modulation. This article uniquely examines mechanistic insights, meta-analytic findings, and practical assay implications for advanced research.

454 records 9/31 page Previous Next First page 上5页 678910 下5页 Last page